Marker | First author | Published studies | Number of eligible studies | Number of patients | Overall HR* | 95% CI | Significance/comment |
---|---|---|---|---|---|---|---|
CI, confidence interval; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; HR, hazard ratio of death for high expression of the marker. | |||||||
*HR>1 implies worse survival for the group with increased expression of the marker, whereas HR<1 (Bcl-2) indicates better survival for the group with higher expression. For p53, the prognostic significance of studies that used Pab1801 and DO7 antibodies were separately analysed. | |||||||
EGFR | Meert6 | Until July 2001 | 8 | 1987 | 1.13 | 1.00 to 1.28 | Weak significance |
P21RAS | Mascaux29 | Until July 2003 | 7 | 989 | 1.08 | 0.86 to 1.34 | Not significant |
HER-2 | Nakamura18 | Until August 2004 | 18 | 2579 | 1.32 | 1.14 to 1.65 | 17/27 negative studies excluded for lack of detailed survival data |
P53 | Steels108 | Until July 1999 | 8 (Pab1801) | 1035 | 1.57 | 1.28 to 1.91 | True significance requires prospective and multivariate confirmation by a standardised technique, scoring criteria and cut-offs |
16 (DO-7) | 2067 | 1.25 | 1.09 to 1.43 | ||||
Ki-67 | Martin61 | Until December 2002 | 16 | 1863 | 1.55 | 1.34 to 1.78 | |
Bcl-2 | Martin129 | 1993 to December 1999 | 18 | 2909 | 0.72 | 0.64 to 0.82 |